Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED, UNRESECTABLE OR METASTATIC, PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS (PNET): A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARS

NCT02264665 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02264665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02264665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED, UNRESECTABLE OR METASTATIC, PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS (PNET): A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARS
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
May 12, 2015
Completion date
November 18, 2019
Enrollment
144 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocrine tumor, well differentiated and progressive